Translumbar type II endoleak embolization with a new liquid iodinated polyvinyl alcohol polymer: Case series and review of current literature.

Giovanni Leati, Francesco Di Bartolomeo, Gabriele Maffi, Luca Boccalon, Domenico Diaco, Edoardo Segalini, Angelo Spinazzola
{"title":"Translumbar type II endoleak embolization with a new liquid iodinated polyvinyl alcohol polymer: Case series and review of current literature.","authors":"Giovanni Leati,&nbsp;Francesco Di Bartolomeo,&nbsp;Gabriele Maffi,&nbsp;Luca Boccalon,&nbsp;Domenico Diaco,&nbsp;Edoardo Segalini,&nbsp;Angelo Spinazzola","doi":"10.3389/fradi.2023.1145164","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To describe our experience with the use of a novel iodized Polyvinyl Alcohol Polymer liquid agent (Easyx) in type II endoleak treatment with translumbar approach.</p><p><strong>Methods: </strong>Our case series is a retrospective review of patients with type II endoleak (T2E) treated with Easyx from December 2017 to December 2020. Indication for treatment was a persistent T2E with an increasing aneurysm sac ≥5 mm on computed tomography angiography (CTA) over a 6-month interval. Technical success was defined as the embolization of the endoleak nidus with reduction or elimination of the T2E on sequent CTA evaluation. Clinical success was defined as an unchanged or decreased aneurysm sac on follow-up CTA. Secondary endpoints included the presence of artifacts in the postprocedural cross-sectional tomographic imaging and post and intraprocedural complications.</p><p><strong>Results: </strong>Ten patients were included in our retrospective analysis. All T2E were successfully embolized. Clinical success was achieved in 9 out of 10 patients (90%). The mean follow-up was 14 3-20 months. No beam hardening artifact was observed in follow-up CT providing unaltered imaging.</p><p><strong>Conclusion: </strong>Easyx is a novel liquid embolic agent with lava-like characteristics and unaltered visibility on subsequent CT examinations. In our initial experience, Easyx showed to have all the efficacy requisites to be an embolization agent for type II EL management. Its efficacy, however, should be evaluated in more extensive studies and eventually compared with other agents.</p>","PeriodicalId":73101,"journal":{"name":"Frontiers in radiology","volume":"3 ","pages":"1145164"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365270/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in radiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fradi.2023.1145164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To describe our experience with the use of a novel iodized Polyvinyl Alcohol Polymer liquid agent (Easyx) in type II endoleak treatment with translumbar approach.

Methods: Our case series is a retrospective review of patients with type II endoleak (T2E) treated with Easyx from December 2017 to December 2020. Indication for treatment was a persistent T2E with an increasing aneurysm sac ≥5 mm on computed tomography angiography (CTA) over a 6-month interval. Technical success was defined as the embolization of the endoleak nidus with reduction or elimination of the T2E on sequent CTA evaluation. Clinical success was defined as an unchanged or decreased aneurysm sac on follow-up CTA. Secondary endpoints included the presence of artifacts in the postprocedural cross-sectional tomographic imaging and post and intraprocedural complications.

Results: Ten patients were included in our retrospective analysis. All T2E were successfully embolized. Clinical success was achieved in 9 out of 10 patients (90%). The mean follow-up was 14 3-20 months. No beam hardening artifact was observed in follow-up CT providing unaltered imaging.

Conclusion: Easyx is a novel liquid embolic agent with lava-like characteristics and unaltered visibility on subsequent CT examinations. In our initial experience, Easyx showed to have all the efficacy requisites to be an embolization agent for type II EL management. Its efficacy, however, should be evaluated in more extensive studies and eventually compared with other agents.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一种新型液体碘化聚乙烯醇聚合物经腰椎II型内漏栓塞术:病例系列和当前文献综述。
目的:描述我们使用一种新型碘化聚乙烯醇聚合物液体剂(Easyx)经腰椎入路治疗II型内漏的经验。方法:我们的病例系列是对2017年12月至2020年12月接受Easyx治疗的II型endoleak (T2E)患者的回顾性分析。治疗的适应症是持续的T2E,在计算机断层血管造影(CTA)上动脉瘤囊增加≥5mm,间隔6个月。技术上的成功被定义为栓塞内漏病灶并在随后的CTA评估中减少或消除T2E。临床成功的定义是在随访的CTA上动脉瘤囊没有改变或减小。次要终点包括术后断层断层成像中的伪影以及术后和术中并发症。结果:10例患者纳入回顾性分析。所有T2E均成功栓塞。10例患者中有9例(90%)取得临床成功。平均随访14 ~ 20个月。随访CT未见光束硬化伪影,影像学未见改变。结论:Easyx是一种新型的液体栓塞剂,具有类似熔岩的特征,在随后的CT检查中可见性不变。在我们的初步经验中,Easyx显示出作为II型EL治疗的栓塞剂所必需的所有疗效。然而,它的疗效应该在更广泛的研究中进行评估,并最终与其他药物进行比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
期刊最新文献
Language task-based fMRI analysis using machine learning and deep learning. Case Report: Diffuse cerebral lymphomatosis with superimposed multifocal primary CNS lymphoma. Diffusion-weighted MRI in the identification of renal parenchymal involvement in children with a first episode of febrile urinary tract infection. SenseCare: a research platform for medical image informatics and interactive 3D visualization. Editorial: Artificial intelligence and multimodal medical imaging data fusion for improving cardiovascular disease care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1